,A review on generation of real-world evidence

被引:0
作者
Shunmugavelu, Meenakshi Sundaram [1 ]
Panda, Jayanta Ku [2 ]
Sehgal, Ashish [3 ]
Makkar, Brij Mohan [4 ]
机构
[1] Trichy Diabet Specialty Ctr, Trichy 620018, Tamil Nadu, India
[2] SCB Med Coll Odisha, Cuttack, Odisha, India
[3] Diabet Med, New Delhi, India
[4] Cleveland Clin, Adv Certificate Courses Diabet, New Delhi, India
来源
CLINICAL DIABETOLOGY | 2021年 / 10卷 / 05期
关键词
real-world evidence; healthcare policies; real-world data; pragmatic trials; policy making; RANDOMIZED CONTROLLED-TRIALS; INSULIN DEGLUDEC; BASAL INSULIN; MULTICENTER; LIMITATIONS; POPULATION; THERAPY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-world evidence can generate credible evidence to inform treatment decisions. Real-world evidence is in developmental stage and is fast evolving yet there are many unexplained attributes of real-world evidence. Real-world evidence informs benefit-risk decisions and is increasingly being used to support regulatory decision making. Potential benefits of real-world data include determination of extended outcomes including long-term outcomes, opportunities to partner with patients in innovative ways, and reduction in time and cost to generate dependable evidence. Limitations of real-world evidence include uncertainty in the quality of datasets and lack methodologic rigor in real-world studies. Use of real-world evidence for healthcare practices and policies is limited. Ensuring completeness, homogeneity, and linkage of datasets can enhance utility for epidemiological investigations and improvement in health outcomes. Research should be strengthened for real-world studies and technical standards should be reinforced. Collaborations of stakeholders is key to formulation and adoption of guidance for real-world evidence. Real-world data cannot be a substitute to randomized clinical studies but can possibly augment the generated evidence.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 46 条
  • [1] Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Board-Blinded 15-Month Study
    Alphs, Larry
    Benson, Carmela
    Cheshire-Kinney, Kimberly
    Lindenmayer, Jean-Pierre
    Mao, Lian
    Rodriguez, Stephen C.
    Starr, H. Lynn
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (05) : 554 - U146
  • [2] [Anonymous], 2019, PDUFA REAUTHORIZATIO
  • [3] [Anonymous], 2019, REAL WORLD EVIDENCE
  • [4] Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States
    Asche, Carl V.
    Zografos, Panagiotis
    Norlin, Jenny M.
    Urbanek, Bill
    Mamay, Carl
    Makin, Charles
    Erntoft, Sandra
    Chen, Chi-Chang
    Hines, Dionne M.
    Siegel, Daniel Mark
    [J]. VALUE IN HEALTH, 2016, 19 (02) : 239 - 248
  • [5] Bhatt Arun, 2019, Perspect Clin Res, V10, P51, DOI 10.4103/picr.PICR_8_19
  • [6] A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function
    Brod, M.
    Wolden, M.
    Christensen, T.
    Bushnell, D. M.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (06) : 546 - 557
  • [7] The limitations of randomized controlled trials in predicting effectiveness
    Cartwright, Nancy
    Munro, Eileen
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2010, 16 (02) : 260 - 266
  • [8] Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study
    Cohen, Cheli Melzer
    Thorsted, Brian Larsen
    Wolden, Michael Lyng
    Chodick, Gabriel
    Karasik, Avraham
    [J]. DIABETES THERAPY, 2017, 8 (05) : 1047 - 1055
  • [9] Dang Amit, 2016, Perspect Clin Res, V7, P156
  • [10] European Medicines Agency, 2017, EMACHMPICH4362212017